Fresenius Medical Care AG Business Summary

Fresenius Medical Care AG (FMS) operates a vertically integrated healthcare model centered on the renal care continuum, generating revenue through three primary segments: Care Delivery, Care Enablement, and Value-Based Care. The Care Delivery segment provides dialysis services across a global network of approximately 3,700 clinics, primarily utilizing a fee-for-service model. Care Enablement functions as the company’s MedTech arm, deriving income from the development and sale of dialysis machines, dialyzers, and related disposables to third-party providers. The Value-Based Care segment, a strategic growth pillar, utilizes an insurance-like model where the company is reimbursed based on patient outcomes and total cost management for chronic kidney disease. Fresenius maintains its position as the global market leader in dialysis services and products, competing directly with DaVita Inc. in clinical services, and Baxter International, B. Braun Melsungen AG, and Nipro Corporation in the medical equipment and technology space. Formed in 1996 through the merger of Fresenius's dialysis business with National Medical Care, the company is currently led by CEO Helen Giza, who previously served as CFO and Chief Transformation Officer following a senior leadership tenure at Takeda Pharmaceuticals. The executive team includes CFO Martin Fischer, formerly of Siemens Healthineers, and Joe Turk, who was appointed CEO of Care Enablement in January 2026 after leading the company’s home and critical care divisions. Further strengthening the clinical leadership, Dr. Charles Hugh-Jones joined as Global Chief Medical Officer in January 2026, bringing a pedigree from Volastra Therapeutics and Pfizer. The company is overseen by a Supervisory Board chaired by Michael Sen, the CEO of Fresenius SE & Co. KGaA, which remains the company’s largest strategic shareholder with approximately a 32% stake.